RepliCel Life Sciences Inc. (REPCF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -311.73 Thousand CAD | 75.8% |
| 2022 | -1.28 Million CAD | 59.81% |
| 2021 | -3.2 Million CAD | -81.73% |
| 2020 | -1.76 Million CAD | 42.14% |
| 2019 | -3.04 Million CAD | -10.08% |
| 2018 | -2.76 Million CAD | 53.96% |
| 2017 | -6.01 Million CAD | -40.81% |
| 2016 | -4.27 Million CAD | 15.32% |
| 2015 | -5.04 Million CAD | 2.97% |
| 2014 | -5.19 Million CAD | -18094.07% |
| 2013 | -28.57 Thousand CAD | 99.15% |
| 2012 | -3.36 Million CAD | 3.74% |
| 2011 | -3.49 Million CAD | -45.33% |
| 2010 | -2.4 Million CAD | -3118.1% |
| 2009 | 79.65 Thousand CAD | 146.78% |
| 2008 | -170.27 Thousand CAD | 71.68% |
| 2007 | -601.18 Thousand CAD | -106.99% |
| 2006 | -290.44 Thousand CAD | 32.06% |
| 2005 | -427.51 Thousand CAD | 56.57% |
| 2004 | -984.4 Thousand CAD | -836.88% |
| 2003 | -105.07 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -251.83 Thousand CAD | -112.42% |
| 2024 Q2 | -187.93 Thousand CAD | 25.37% |
| 2023 Q3 | -818.6 Thousand CAD | -46.66% |
| 2023 Q1 | -1.19 Million CAD | -152.82% |
| 2023 FY | -311.73 Thousand CAD | 75.8% |
| 2023 Q2 | -558.15 Thousand CAD | 53.47% |
| 2023 Q4 | 2.02 Million CAD | 347.79% |
| 2022 Q2 | -1.16 Million CAD | -44.38% |
| 2022 FY | -1.28 Million CAD | 59.81% |
| 2022 Q1 | -808.01 Thousand CAD | 3.0% |
| 2022 Q4 | 2.27 Million CAD | 288.68% |
| 2022 Q3 | -1.2 Million CAD | -3.17% |
| 2021 Q1 | -1.35 Million CAD | -432.68% |
| 2021 Q3 | -836.08 Thousand CAD | 20.29% |
| 2021 Q4 | -832.99 Thousand CAD | 0.37% |
| 2021 Q2 | -1.04 Million CAD | 22.61% |
| 2021 FY | -3.2 Million CAD | -81.73% |
| 2020 Q4 | -254.43 Thousand CAD | 57.45% |
| 2020 Q2 | -329.48 Thousand CAD | 8.64% |
| 2020 Q1 | -360.65 Thousand CAD | 41.02% |
| 2020 FY | -1.76 Million CAD | 42.14% |
| 2020 Q3 | -597.99 Thousand CAD | -81.5% |
| 2019 Q3 | -576.03 Thousand CAD | 38.67% |
| 2019 Q2 | -939.16 Thousand CAD | -13.56% |
| 2019 FY | -3.04 Million CAD | -10.08% |
| 2019 Q4 | -611.5 Thousand CAD | -6.16% |
| 2019 Q1 | -827.04 Thousand CAD | 9.33% |
| 2018 FY | -2.76 Million CAD | 53.96% |
| 2018 Q2 | -599.34 Thousand CAD | -21.7% |
| 2018 Q1 | -492.46 Thousand CAD | 20.46% |
| 2018 Q4 | -912.19 Thousand CAD | -19.23% |
| 2018 Q3 | -765.08 Thousand CAD | -27.65% |
| 2017 Q4 | -619.17 Thousand CAD | 47.92% |
| 2017 Q3 | -1.18 Million CAD | 52.34% |
| 2017 Q2 | -2.49 Million CAD | -45.73% |
| 2017 Q1 | -1.71 Million CAD | 3.39% |
| 2017 FY | -6.01 Million CAD | -40.81% |
| 2016 Q2 | -777.36 Thousand CAD | 27.33% |
| 2016 Q4 | -1.77 Million CAD | -171.5% |
| 2016 FY | -4.27 Million CAD | 15.32% |
| 2016 Q1 | -1.06 Million CAD | 17.71% |
| 2016 Q3 | -652.54 Thousand CAD | 16.06% |
| 2015 FY | -5.04 Million CAD | 2.97% |
| 2015 Q4 | -1.29 Million CAD | -9.77% |
| 2015 Q3 | -1.18 Million CAD | 13.05% |
| 2015 Q2 | -1.36 Million CAD | -13.7% |
| 2015 Q1 | -1.19 Million CAD | 12.54% |
| 2014 Q2 | -1.41 Million CAD | -19.78% |
| 2014 Q3 | -1.22 Million CAD | 13.69% |
| 2014 Q1 | -1.18 Million CAD | -13.74% |
| 2014 FY | -5.19 Million CAD | -18094.07% |
| 2014 Q4 | -1.36 Million CAD | -11.81% |
| 2013 FY | -28.57 Thousand CAD | 99.15% |
| 2013 Q4 | -1.04 Million CAD | -139.86% |
| 2013 Q2 | -843.12 Thousand CAD | -11.35% |
| 2013 Q3 | 2.61 Million CAD | 409.97% |
| 2013 Q1 | -757.17 Thousand CAD | -7.0% |
| 2012 Q1 | -751.46 Thousand CAD | 4.7% |
| 2012 Q2 | -1.64 Million CAD | -118.39% |
| 2012 Q4 | -707.62 Thousand CAD | -1844.39% |
| 2012 Q3 | -36.39 Thousand CAD | 97.78% |
| 2012 FY | -3.36 Million CAD | 3.74% |
| 2011 Q3 | -890.77 Thousand CAD | 19.16% |
| 2011 Q1 | -713.38 Thousand CAD | 70.95% |
| 2011 Q2 | -1.1 Million CAD | -54.46% |
| 2011 Q4 | -788.51 Thousand CAD | 11.48% |
| 2011 FY | -3.49 Million CAD | -45.33% |
| 2010 Q3 | 4864.00 CAD | -91.19% |
| 2010 Q2 | 55.2 Thousand CAD | 749.19% |
| 2010 Q1 | -8503.00 CAD | 71.65% |
| 2010 Q4 | -2.45 Million CAD | -50586.41% |
| 2010 FY | -2.4 Million CAD | -3118.1% |
| 2009 Q3 | -2951.00 CAD | -101.81% |
| 2009 Q4 | -29.99 Thousand CAD | -916.47% |
| 2009 Q2 | 163.1 Thousand CAD | 422.97% |
| 2009 Q1 | -50.5 Thousand CAD | 18.22% |
| 2009 FY | 79.65 Thousand CAD | 146.78% |
| 2008 Q1 | -43.83 Thousand CAD | 40.45% |
| 2008 Q4 | -61.74 Thousand CAD | -50.23% |
| 2008 Q3 | -41.1 Thousand CAD | -71.39% |
| 2008 Q2 | -23.98 Thousand CAD | 45.29% |
| 2008 FY | -170.27 Thousand CAD | 71.68% |
| 2007 Q3 | -122.48 Thousand CAD | -88.4% |
| 2007 Q1 | -340.79 Thousand CAD | -29.27% |
| 2007 FY | -601.18 Thousand CAD | -106.99% |
| 2007 Q4 | -73.61 Thousand CAD | 39.9% |
| 2007 Q2 | -65.01 Thousand CAD | 80.92% |
| 2006 Q3 | -89.26 Thousand CAD | -164.17% |
| 2006 Q1 | -76.62 Thousand CAD | -51.56% |
| 2006 FY | -290.44 Thousand CAD | 32.06% |
| 2006 Q4 | -263.63 Thousand CAD | -195.34% |
| 2006 Q2 | 139.11 Thousand CAD | 281.54% |
| 2005 Q3 | -161.14 Thousand CAD | -31.56% |
| 2005 FY | -427.51 Thousand CAD | 56.57% |
| 2005 Q2 | -122.48 Thousand CAD | -31.85% |
| 2005 Q1 | -92.89 Thousand CAD | 85.74% |
| 2005 Q4 | -50.56 Thousand CAD | 68.62% |
| 2004 Q1 | -19.52 Thousand CAD | 0.0% |
| 2004 Q2 | -18.8 Thousand CAD | 3.67% |
| 2004 Q4 | -651.6 Thousand CAD | -129.09% |
| 2004 FY | -984.4 Thousand CAD | -836.88% |
| 2004 Q3 | -284.43 Thousand CAD | -1412.5% |
| 2003 Q2 | - USD | 0.0% |
| 2003 FY | -105.07 Thousand CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 76.657% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 100.479% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 50.707% |
| Nascent Biotech, Inc. | -2.08 Million USD | 85.068% |
| Qrons Inc. | -789.34 Thousand USD | 60.507% |
| Regen BioPharma, Inc. | 1.02 Million USD | 130.457% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 100.588% |
| BioStem Technologies, Inc. | -8.48 Million USD | 96.325% |
| Skye Bioscience, Inc. | -37.64 Million USD | 99.172% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 24.97% |
| Rebus Holdings, Inc. | -1.02 Million USD | 69.438% |
| CSL Limited | 2.64 Billion USD | 100.012% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 99.502% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 91.837% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 98.036% |
| Adynxx, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 95.536% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 99.584% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 95.26% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -14.02% |
| SQZ Biotechnologies Company | -79.46 Million USD | 99.608% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 89.222% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 82.877% |
| Mesoblast Limited | -87.95 Million USD | 99.646% |
| Marizyme, Inc. | -65.34 Million USD | 99.523% |
| Genus plc | 7.9 Million USD | 103.946% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 97.138% |
| Pharming Group N.V. | -10.54 Million USD | 97.045% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 85.633% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 91.598% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 96.475% |
| ContraFect Corporation | -65.15 Million USD | 99.522% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 93.62% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 81.954% |
| IMV Inc. | -36.48 Million USD | 99.146% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 96.132% |
| MultiCell Technologies, Inc. | -380.07 USD | -81920.154% |
| ONE Bio Corp. | 8.67 Million USD | 103.593% |
| Accustem Sciences Inc. | -3.74 Million USD | 91.679% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 99.397% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 75.398% |
| Q BioMed Inc. | -2.05 Million USD | 84.809% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 91.649% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 86.907% |
| Biomind Labs Inc. | -1.21 Million USD | 74.328% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 99.478% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 89.95% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 96.056% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 84.007% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -1981.557% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 94.641% |
| GB Sciences, Inc. | -1.36 Million USD | 77.107% |
| Alpha Cognition Inc. | -13.77 Million USD | 97.737% |
| HST Global, Inc. | -146.21 Thousand USD | -113.21% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 82.235% |
| Halberd Corporation | -79.67 Thousand USD | -291.252% |
| Enzolytics Inc. | -2.17 Million USD | 85.679% |
| Agentix Corp. | -1.37 Million USD | 77.315% |
| Resverlogix Corp. | -3.61 Million USD | 91.365% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 90.171% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.894% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 418.096% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 104.502% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 92.154% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 89.699% |
| AVAX Technologies, Inc. | -6.41 Million USD | 95.14% |
| Zenith Capital Corp. | -10.59 Million USD | 97.058% |
| Genscript Biotech Corporation | -95.47 Million USD | 99.673% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -1241.253% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 92.481% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -415.769% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 84.453% |
| Kadimastem Ltd | -3.3 Million USD | 90.575% |
| Helix BioMedix, Inc. | -1.05 Million USD | 70.481% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 29.371% |
| LadRx Corporation | 400.44 Thousand USD | 177.847% |
| Cell Source, Inc. | -5.32 Million USD | 94.142% |
| Regen BioPharma, Inc. | 1.02 Million USD | 130.457% |
| NovAccess Global Inc. | -4.76 Million USD | 93.464% |
| Affymax, Inc. | -14.42 Million USD | 97.839% |
| Itoco Inc. | -1.86 Million USD | 83.321% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 92.983% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 81.322% |
| Mobile Lads Corp. | -2.26 Million USD | 86.227% |
| CytoDyn Inc. | -49.84 Million USD | 99.375% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -294.435% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -36.649% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 66.891% |
| SYBLEU INC | -180.3 Thousand USD | -72.894% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 80.67% |
| International Stem Cell Corporation | -131 Thousand USD | -137.965% |
| Bioxytran, Inc. | -4.28 Million USD | 92.716% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -474.392% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 87.68% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 99.352% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 85.254% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 60.079% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 90.16% |
| Neutra Corp. | -233.46 Thousand USD | -33.525% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 98.464% |
| PureTech Health plc | -65.69 Million USD | 99.525% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 98.534% |
| IXICO plc | -1.17 Million USD | 73.537% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 96.86% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 99.454% |
| CSL Limited | 2.64 Billion USD | 100.012% |
| Cellectis S.A. | -103.17 Million USD | 99.698% |